Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Artificial intelligence enhanced prognostication in rare Acute Myeloid Leukemia subtypes with BCR::ABL1 and inv(3)/t(3;): A systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

PDPrachi Dawer

Discussion

Loading...

Member takes

Overview

Systematic review reveals limited AI models for prognostication in rare AML subtypes, suggesting a need for better risk stratification and prognostic measures.

Key Points

  • This systematic review aims to evaluate the application of AI in prognostication for rare subtypes of Acute Myeloid Leukemia.
  • Comprehensive search of PubMed, Embase, Scopus, and IEEE Xplore from 2010 to June 2025 using PRISMA guidelines.
  • Inclusion of original research studying AI/ML for AML with specific focus on rare subtypes.
  • Quality assessment utilized TRIPOD-AI and PROBAST frameworks.
  • Only 7 relevant studies identified, with 3 focused on the target subtypes.
  • One study distinguished AML with BCR::ABL1 based on unique transcriptome profiling.
  • Another study demonstrated moderate prognostic ability of a texture-based AI model in a mixed AML/MDS population, with AUC of 0.71 and HR of 2.38.

Cite This Study

Prachi Dawer (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1cahttps://doi.org/10.1182/blood-2025-7878
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Towards Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review2025 · 1 citations
  2. 2Research advances in the adjunctive diagnosis of acute myeloid leukemia2025 · 2 citations
  3. 3AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq2025
  4. 4Evaluating artificial intelligence (AI) as a clinical decision support tool for AML patients2025 · 1 citations
  5. 5AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia2025